4.5 Review

EZH2 inhibition: a promising strategy to prevent cancer immune editing

期刊

EPIGENOMICS
卷 12, 期 16, 页码 1457-1476

出版社

FUTURE MEDICINE LTD
DOI: 10.2217/epi-2020-0186

关键词

cancer immunotherapy; epigenetics; EZH2; immune editing

资金

  1. Higher Education Innovation Fund (HEIF-UK)
  2. Canadian Foundation for Translational Immunology
  3. CIHR [141635, 144159, 153081]
  4. TFRI program project [1062]
  5. MITACS [IT14958]
  6. National Cancer Institute [P50CA097186]

向作者/读者索取更多资源

Immunotherapies are revolutionizing the clinical management of a wide range of cancers. However, intrinsic or acquired unresponsiveness to immunotherapies does occur due to the dynamic cancer immunoediting which ultimately leads to immune escape. The evolutionarily conserved histone modifier enhancer of zeste 2 (EZH2) is aberrantly overexpressed in a number of human cancers. Accumulating studies indicate that EZH2 is a main driver of cancer cells' immunoediting and mediate immune escape through downregulating immune recognition and activation, upregulating immune checkpoints and creating an immunosuppressive tumor microenvironment. In this review, we overviewed the roles of EZH2 in cancer immunoediting, the preclinical and clinical studies of current pharmacologic EZH2 inhibitors and the prospects for EZH2 inhibitor and immunotherapy combination for cancer treatment.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据